1
|
Proton beam radiotherapy of locally advanced or recurrent conjunctival squamous cell carcinoma: experience of the CATANA Centre. JOURNAL OF RADIOTHERAPY IN PRACTICE 2020. [DOI: 10.1017/s1460396920000953] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
AbstractAim:Conjunctival squamous cell carcinoma (SCC) is a rare tumour of the ocular region and microscopic radical surgical is difficult. There are no single guidelines for therapeutic management and the role of radiation therapy is not clearly defined although conventionally photon or electron beams are used. Proton beam radiotherapy (PBRT) is a new option for a conservative approach and allows good sparing of the organs at risk.Materials and methods:After surgical resection, we collected 15 cases treated at our institution with PBRT. The dose delivered was between 48 and 60 Gy relative biological effectiveness (RBE), with fractions of 12–15 Gy RBE.Results:After an average period of 48 months, the patients achieved excellent disease control (overall survival and disease-free survival: 86·6%), with minimal acute and late toxicity.Findings:In this work, we present our experience on the use of PBRT technique in SCC treatment. A larger sample of patients is needed to draw conclusions about the impact of this treatment on disease recurrence and overall survival.
Collapse
|
2
|
Metachronous NSCLC in previously irradiated patients: is re-irradiation with SBRT a good option as definitive treatment? JOURNAL OF RADIOTHERAPY IN PRACTICE 2019. [DOI: 10.1017/s1460396919000773] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
AbstractAim:Treatment of metachronous second primary non-small cell lung cancer (NSCLC) in patients already treated with definitive radiotherapy is a matter of debate, since most patients are excluded from surgical treatment, which remains a therapeutic standard for patients with isolated lung masses. Salvage chemotherapy or immunotherapy alone offers a low probability of disease control. The option of re-irradiation often remains the only viable, but the risks of severe acute or late toxicities affecting the surrounding normal tissues make this a real clinical challenge.Materials and methods:From January 2015 to April 2018, five patients (male/female: 4/1; age 54–81 years, median 68) with previously irradiated NSCLC presented with a second primary lung tumour.Results:A partial response was seen in four patients, one complete responses in the fifth. The toxicity was low: two patients experienced a grade 2 asymptomatic radiation pneumonitis after 6 and 12 months from the end of stereotactic body radiation therapy, resolved with cortisone therapy. No acute or late oesophageal or cardiac toxicity was found.Findings:In this work, we present our initial experience about the use of stereotactic radiotherapy technique in already irradiated patients. We reported a local disease control in all cases with an acceptable toxicity.
Collapse
|
3
|
Spatola C, Tocco A, Marletta D, Milazzotto R, Marletta F, Pergolizzi S, Migliore M, Basile A, Privitera G, Acquaviva G. Adenoid cystic carcinoma of trachea: long-term disease control after endoscopic surgery and radiotherapy. Future Oncol 2019; 16:33-39. [PMID: 31793391 DOI: 10.2217/fon-2018-0685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: Adenoid cystic carcinoma is a rare tumor of head and neck region and its development in the thoracic region is even less frequent. This implies the absence of guidelines for therapeutic management and a consequent case-by-case approach. The role of radiotherapy is not yet clearly defined, but intensity-modulated radiotherapy allows for improved organ-at-risk sparing. Materials & methods: We have collected the cases of four patients treated at our institutions by the means of intensity-modulated radiotherapy, after endoscopic resection. Results & conclusion: Patients treated achieved long-term disease control of about 5 years, with a minimal acute toxicity. Longer follow-up is needed to drain conclusion on the impact of this treatment on overall survival.
Collapse
Affiliation(s)
- Corrado Spatola
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania 95125, Italy
| | - Alessandra Tocco
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania 95125, Italy
| | - Dario Marletta
- UOC Radioterapia AOOE Cannizzaro di Catania 95100, Italy
| | - Roberto Milazzotto
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania 95125, Italy
| | | | | | | | - Antonio Basile
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania 95125, Italy
| | - Giuseppe Privitera
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania 95125, Italy
| | | |
Collapse
|
4
|
Spatola C, Tocco A, Pagana A, Milazzotto R, Luigi R, Salamone V, Militello C, Migliore M, Foti PV, Cataldo AD, Acquaviva G, Privitera G. Combined taxane-based chemotherapy and intensity-modulated radiotherapy with simultaneous integrated boost for gastroesophageal junction adenocarcinoma. Future Oncol 2018; 14:47-51. [DOI: 10.2217/fon-2017-0342] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
We describe our experience, gained over the past 3 years, in the treatment of gastroesophageal junction adenocarcinoma, whose incidence has been increasing in recent years. In our series, we present the results to a follow-up of about 2 years for a total of 18 patients, treated with a particularly intensive combination treatment. It consists of neoadjuvant induction chemotherapy with the protocol docetaxel-cisplatin-5-fluorouracil for four cycles, before a concomitant chemoradiotherapy treatment. During combined phase, patients received an intensity-modulated radiotherapy and a weekly cisplatin. We will present the data to a long follow-up time and we will discuss the literature, the integration with thoracoabdominal surgery and other specific issues of this pathology.
Collapse
Affiliation(s)
- Corrado Spatola
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania, 95125, Italy
| | - Alessandra Tocco
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania, 95125, Italy
| | - Antonio Pagana
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania, 95125, Italy
| | - Roberto Milazzotto
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania, 95125, Italy
| | - Raffaele Luigi
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania, 95125, Italy
| | - Vincenzo Salamone
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania, 95125, Italy
| | - Carmelo Militello
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania, 95125, Italy
| | | | - Pietro Valerio Foti
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania, 95125, Italy
| | - Antonio Di Cataldo
- UOC Chirurgia Digerente e colo-rettale, AOU Policlinico-VE Catania, Italy
| | | | - Giuseppe Privitera
- UOC Radiodiagnostica e Radioterapia, AOU Policlinico-VE di Catania, 95125, Italy
| |
Collapse
|
5
|
Parker J, Dennis-Beron S. Welcome to the 13th volume of Future Oncology. Future Oncol 2016; 13:1-3. [PMID: 27905256 DOI: 10.2217/fon-2016-0446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Jade Parker
- Future Science Group, Unitec House, 2 Albert Place, London, N31QB, UK
| | | |
Collapse
|